# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JMP Securities analyst Silvan Tuerkcan reiterates Elevation Oncology (NASDAQ:ELEV) with a Market Outperform and maintains $7...
Following recently signed clinical supply agreements with Eli Lilly and Company (Lilly) and GSK, respectively, Elevation Oncolo...
Piper Sandler analyst Biren Amin initiates coverage on Elevation Oncology (NASDAQ:ELEV) with a Overweight rating and announc...
Stephens & Co. analyst Sudan Loganathan initiates coverage on Elevation Oncology (NASDAQ:ELEV) with a Overweight rating ...
Wedbush analyst Robert Driscoll reiterates Elevation Oncology (NASDAQ:ELEV) with a Outperform and maintains $8 price target.